Klebsiella pneumoniae and Acinetobacter baumannii are both major contributors to the global antimicrobial resistance crisis, causing rapidly progressive and often severe infections. Researchers from Vaxdyn SL and collaborators presented efficacy data for K-Vax, an inactivated, LPS-null whole-cell A. baumannii-based vaccine engineered to display conserved K. pneumoniae outer-membrane proteins on the bacterial cell surface.
At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.
New treatment options for treating Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M. abscessus. The aim of this new study was to focus on the activity of MRX-5, the oral prodrug of MRX-6038, both in vivo and in vitro.
